Почетна › Множен миелом › Мериленд
Клинички испитувања за Множен миелом во Мериленд
25 студии за Множен миелом бараат учесници на локации во Мериленд.
Градови во Мериленд
Официјален текст на студијата (англиски)
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Се регрутираРана фаза 1
Возраст 18 и постари · Сите полови · Ажурирано 5.10.2026 · NCT06398457Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
- National Institutes of Health Clinical Center, Bethesda
Се регрутираФаза 1
Возраст од 18 до 120 · Сите полови · Ажурирано 5.10.2026 · NCT06904066Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
- National Institutes of Health Clinical Center, Bethesda
Се регрутираНабљудувачка студија
Возраст од 18 до 120 · Сите полови · Ажурирано 28.9.2026 · NCT02682667Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- National Institutes of Health Clinical Center, Bethesda
Се регрутираФаза 2
Возраст од 18 до 72 · Сите полови · Ажурирано 28.9.2026 · NCT03412877Tissue Collection for Studies of Lymph Cancer
- National Institutes of Health Clinical Center, Bethesda
Се регрутираНабљудувачка студија
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT01676805A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- University of Maryland School of Medicine, Baltimore
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07258511A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Johns Hopkins Hospital, Baltimore
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07518186Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda
Се регрутираФаза 4
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07609940A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Johns Hopkins University School of Medicine JHUSOM, Baltimore
- Center for Cancer and Blood Disorders, Bethesda
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT0555222218F-Fluciclovine PET/CT in Multiple Myeloma
- National Institutes of Health Clinical Center, Bethesda
Се регрутираФаза 2
Возраст од 18 до 120 · Сите полови · Ажурирано 22.9.2026 · NCT06103838Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Johns Hopkins Asthma & Allergy Center, Baltimore
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 21.9.2026 · NCT07648264Collection of Tissue Samples for Cancer Research
- Johns Hopkins University, Baltimore
- National Institutes of Health Clinical Center, Bethesda
Се регрутираНабљудувачка студија
2 Months · Сите полови · Ажурирано 16.9.2026 · NCT00900198A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- University of Maryland | Greenebaum Cancer Center, Baltimore
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 9.9.2026 · NCT06980480A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
- Maryland Oncology Hematology, Columbia
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 4.9.2026 · NCT07637578A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Bethesda
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 25.8.2026 · NCT07227311Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Baltimore
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 14.8.2026 · NCT07764978A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- University of Maryland Greenbaum Comprehensive Cancer Center, Baltimore
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 12.8.2026 · NCT07280013A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Maryland Oncology Hematology - Silver Spring /ID# 268562, Silver Spring
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 13.7.2026 · NCT05650632Integrated Cancer Repository for Cancer Research
- Northwest Hospital, Randallstown
- William E. Kahlert Regional Cancer Center, Westminster
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
Возраст од 19 до 110 · Сите полови · Ажурирано 29.6.2026 · NCT02012699Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- The Center for Cancer and Blood Disorders (CCBD), Bethesda
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 24.6.2026 · NCT04068597Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Greater Baltimore Medical Center, Baltimore
Се регрутираФаза 3
Сите возрасти · Сите полови · Ажурирано 10.6.2026 · NCT05561387Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Greenebaum Cancer Center UM of MD, Baltimore
- John Hopkins, Baltimore
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 4.6.2026 · NCT05243797Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Maryland Oncology Hematology, Columbia
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 22.4.2026 · NCT05972135A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Sibley Memorial Hospital, Baltimore
- University of Maryland, Baltimore
- Johns Hopkins Main Center, Baltimore
Се регрутираФаза 1/2
Возраст 12 и постари · Сите полови · Ажурирано 24.3.2026 · NCT04988555A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
- Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 5.9.2025 · NCT05372354Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.